A Study of Replagal in Treatment-naïve Adults With Fabry Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

December 16, 2022

Study Completion Date

December 16, 2022

Conditions
Fabry Disease
Interventions
DRUG

REPLAGAL

Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.

Trial Locations (28)

3010

Hospital General Universitario de Alicante, Alicante

4009

Hospital de Torrecárdenas, Almería

8035

Hospital Universitario Vall d'Hebrón - PPDS, Barcelona

10117

Charité - Universitätsklinikum, Berlin

11527

Laiko General Hospital of Athens, Athens

12462

Attikon University General Hospital, Athens

17674

Onasseio Private Practise Hospital of Piraeus, Kallithea

28046

Hospital Universitario La Paz, Madrid

41013

Hospital Universitario Virgen del Rocio - PPDS, Seville

45500

University Hospital of Ioannina, Ioannina

50012

Hospital Quironsalud Zaragoza, Zaragoza

54645

Papageorgiou General Hospital of Thessaloniki, Thessaloniki

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

65130

Vaasan Keskussairaala, Vaasa

65239

SphinCS, Höchheim

71500

University General Hospital of Heraklion, Heraklion

75185

Akademiska Sjukhuset I Uppsala, Uppsala

79379

Fachinternistische Gemeinschaftspraxis, Müllheim

97080

Universitaetsklinikum Wuerzburg, Würzburg

AB T2E 7Z4

M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary, Calgary

B3H 1V7

Queen Elizabeth II Health Sciences Center, Halifax

FI-20521

Turun Yliopistollinen Keskussairaala, Turku

30-033

Szpital Uniwersytecki, Krakow

04-628

Narodowy Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego - Instytut Badaw, Warsaw

50-556

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw

3000-459

Centro Hospitalar e Universitário de Coimbra EPE, Coimbra

4835-044

Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães

1649-035

Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT04840667 - A Study of Replagal in Treatment-naïve Adults With Fabry Disease | Biotech Hunter | Biotech Hunter